Protara Therapeutics, Inc.
TARA Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$2.47
KIRA · Stoqly’s AI analyst, in plain words
- Protara Therapeutics, Inc. lost $57.4M in fiscal 2025.
- Free cash flow was −$56.5M in fiscal 2025, — of revenue.
Market cap
$151M
P/E
—
Revenue
—
Net income
−$57.4M
Free cash flow
−$56.5M
Operating margin
—
Protara Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$57.4M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Protara Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 10, 2026
- Legal name
- Protara Therapeutics, Inc.
- CIK
- 0001359931
Protara Therapeutics, Inc. · TARA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$47.3M | −$66.0M | −$40.4M | −$44.6M | −$57.4M |
| Diluted EPS | −$4.21 | −$5.86 | −$3.57 | −$2.17 | −$1.34 |
| Cash | |||||
| Cash from operations | −$34.5M | −$26.5M | −$37.6M | −$35.8M | −$56.4M |
| Capital expenditure | $0.6M | $0.1M | $0.0M | $0.1M | $0.1M |
| Free cash flow | −$35.1M | −$26.6M | −$37.6M | −$35.9M | −$56.5M |
| Share buybacks | $0.2M | $0.1M | $0.1M | — | — |
| Share count change | 55.3% | 0.2% | 0.6% | 81.7% | 108.0% |
| Debt and strength | |||||
| Cash and short-term investments | $91.2M | $84.4M | $65.6M | $170M | $156M |
| Debt incl. finance leases | $0.0M | — | — | — | — |
| Shareholders' equity | $162M | $102M | $68.3M | $167M | $196M |
| Current ratio | 21.7x | 15.0x | 11.2x | 15.7x | 14.6x |
| Returns and quality | |||||
| Return on capital | −53.1% | — | — | — | — |
| Return on equity | −26.2% | −50.0% | −47.4% | −37.9% | −31.6% |
| Return on tangible equity | 35.7% | −64.6% | −59.2% | −26.7% | −29.2% |
| Piotroski F-score | 1 | — | — | — | — |
| Altman Z'' | 15.7 | 5.6 | −0.0 | 11.9 | 13.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.0M
2 insiders
Of sales under plans
12%
$0.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Protara Therapeutics, Inc. · TARA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.47 a share, the company is worth $151M.
Source: SEC EDGAR XBRL filings (CIK 0001359931). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.